Examination of Idiopathic Hypogonadotropic Hypogonadism (IHH)and Kallmann Syndrome (KS)
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to examine how Kallmann syndrome (KS) and idiopathic
hypogonadotropic hypogonadism (IHH) affect reproductive hormones. These disorders are caused
by a defect in Gonadotropin Releasing Hormone (GnRH) secretion. GnRH is a hormone released by
a small gland in the brain called the hypothalamus. When GnRH is released, it signals another
gland in the brain, the pituitary, to secrete the reproductive hormones that influence sex
hormone (testosterone, estrogen) levels and gamete (sperm, egg cell) production.
This study involves a detailed evaluation and 24-48 hours stay at the hospital.
In this study, males and females ages 16 and older with IHH have a detailed evaluation which
involves an overnight study at the hospital. Some men (18 years and older) may continue on to
receive treatment with pulsatile GnRH. This treatment replaces the hormone which is absent in
IHH and results in normalized testosterone and typically is effective in developing
fertility.
Phase:
N/A
Details
Lead Sponsor:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Massachusetts General Hospital